Prasugrel and cancer: An uncertain association or a credible risk that meaningfully alters the benefit-risk balance

Archives of Internal Medicine

Volumn 170, Issue 12, 2010, Pages 1010-1012

  Kaul, Sanjay ^a   Diamond, George A ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL;

ACUTE CORONARY SYNDROME; BLEEDING; COLON CANCER; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; NEOPLASM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SKIN CANCER; TUMOR PROMOTION;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; COLORECTAL NEOPLASMS; HUMANS; INCIDENCE; LUNG NEOPLASMS; MICE; MYOCARDIAL INFARCTION; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; PREOPERATIVE CARE; RECEPTORS, PURINERGIC P2; RISK FACTORS; STROKE; THIOPHENES; UNITED STATES;

EID: 77954183557     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2010.139     Document Type: Editorial

References (16)

1. Center for Drug Evaluation and Research. Prasugrel label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/022307s000lbl.pdf. Accessed February 24, 2010.
2. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.
3. Food and Drug Administration. New Drug Application 22-307.182 (Marciniak TA. Secondary review of cancer adverse events and risk/benefit [May 6, 2009] [Medical Reviews, Parts 18 to 25]). http://www.accessdata.fda.gov/drugsatfda- docs/nda/2009/022307s000TOC.cfm. Accessed February 24, 2010.
4. Unger EF. Weighing benefits and risks - the FDA's review of prasugrel. N Engl J Med. 2009;361(10):942-945.
5. Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med. 2010;170(12):1078-1080.
6. Paskett ED, Reeves KW, Rohan TE, et al. Association between cigarette smoking and colorectal cancer in the women's health initiative. J Natl Cancer Inst. 2007; 99(22):1729-1735.
7. Lee WJ, Sandler DP, Blair A, Samanic C, Cross AJ, Alavanja MC. Pesticide use and colorectal cancer risk in the Agricultural Health Study. Int J Cancer. 2007;121 (2):339-346. (Pubitemid 46917703)
8. Ritz B, Zhao Y, Krishnadasan A, Kennedy N, Morgenstern H. Estimated effects of hydrazine exposure on cancer incidence and mortality in aerospace workers. Epidemiology. 2006;17(2):154-161.
9. FDA Division of Cardiovascular and Renal Drugs. Cardiovascular and Renal Drugs Advisory Committee briefing document: Effient (prasugrel) acute coronary syndromes managed by percutaneous coronary intervention. http://www.fda.gov/ ohrms/dockets/ac/09/briefing/2009-4412b1-03-Lilly.pdf. Accessed February 24, 2010.
10. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med. 2008;359(13):1400-1402.
11. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008;359(13):1357-1366.
12. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS). http://clinicaltrials.gov/ct2/show/NCT00699998. Accessed April 6, 2010.
13. Goodman SN. Stopping at nothing? some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146(12):882-887.
14. Serebruany VL. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks. Fundam Clin Pharmacol. 2009;23(4):411-417.
15. Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11):1045-1057.
16. Kaul S, Diamond GA. Trial and error: how to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol. 2010;55(5):415-427.